Octreotide Side Effects: Safety Signals and Warnings
Octreotide safety concerns are compound-specific. The main listed side effects are Diarrhea and steatorrhea, Abdominal pain and nausea, and Cholelithiasis. The main warning signals are Gallstones - periodic gallbladder ultrasound recommended, Glucose metabolism changes - monitor in diabetic patients, and Cardiac conduction changes - use caution with beta-blockers and calcium channel blockers.
Direct Answer
Octreotide (Sandostatin) is FDA-approved for acromegaly, carcinoid syndrome, and VIPoma with an extensive evidence base spanning 35+ years of clinical use. As the first synthetic somatostatin analog approved, it remains the most widely used in its class. Multiple Phase 3 trials and decades of real-world data make it the reference compound for somatostatin pharmacology.
- Evidence grade
- Level A
- Research status
- FDA Approved
- Category
- Growth Hormone
- Best for
- Acromegaly, carcinoid syndrome, VIPoma, GH/IGF-1 suppression, somatostatin analog pharmacology
Reported Side Effects
- Diarrhea and steatorrhea
- Abdominal pain and nausea
- Cholelithiasis
- Injection site pain
- Hyperglycemia or hypoglycemia
- Bradycardia
Warnings
- Gallstones - periodic gallbladder ultrasound recommended
- Glucose metabolism changes - monitor in diabetic patients
- Cardiac conduction changes - use caution with beta-blockers and calcium channel blockers
- Thyroid function suppression with long-term use
- Vitamin B12 deficiency with chronic use
Known or Plausible Interactions
- Insulin and oral hypoglycemics (dose adjustment needed)
- Cyclosporine (decreased cyclosporine levels)
- Beta-blockers (additive bradycardia)
- Bromocriptine (increased bromocriptine bioavailability)
Regulatory Context
FDA-approved for acromegaly, severe diarrhea/flushing associated with metastatic carcinoid tumors, and profuse watery diarrhea associated with VIPomas. Available by prescription. Marketed as Sandostatin by Novartis. Generic versions available.
Evidence Snapshot
| Evidence grade | Level A |
|---|---|
| Research status | FDA Approved |
| Best supported outcomes | Acromegaly Control (Level A), Carcinoid Symptom Control (Level A), Gallstone Formation (Level A), and VIPoma Symptom Control (Level A) |
| Primary citation count | 3 |
| Last reviewed | 2026-04-04 |
Related Guides
How to Cite This Page
ExaminePeptides. "Octreotide Side Effects: Safety Signals and Warnings." Last reviewed 2026-04-04. https://examinepeptides.com/answers/octreotide-side-effects-safety/
This static answer page is built for fast indexing and direct citation. It summarizes the matching full evidence review and links back to primary sources where the source database includes them.